Come see us at Booth 207 in Baltimore!
If you are in Baltimore for the DIA Global Pharmacovigilance and Risk Management Strategies Conference, please stop by Booth 207 and say hello!
If you are in Baltimore for the DIA Global Pharmacovigilance and Risk Management Strategies Conference, please stop by Booth 207 and say hello!
Visit the World Drug Safety Congress Americas page on LinkedIn for more information and to purchase tickets for this year’s meeting. See you there!
A clinical executive summary (CES) is a concise document that provides a high-level summary of information regarding a specific product. It presents the most recent, relevant, scientifically accurate and balanced…
The entire team at Med Communications would like to wish our clients, prospects, colleagues, and friends a safe, restful, and joyous holiday.
Developing a contact center relationship is an investment of time, energy, and finance that can yield countless returns if the relationship is valued and viewed as a partnership. Building trust…
Dr. Maria Anitan, Global Head of Pharmacovigilance and Drug Safety, and our knowledgeable PV Quality Manager Ana Augusto are representing Med Communications at the European Pharmacovigilance Congress this week. One of the most…
A small biopharmaceutical client needed a call center and assistance with the launch of a rare disease product. They had a limited budget, a two-person Med Affairs team, and only…
Pharmaceutical companies strive to ensure that the right patients have access to their products through appropriate coverage from drug coverage plans (Payors). Payors have well-established procedures for carefully considering the…
Managed care organizations and health care decision-makers use AMCP formulary dossiers for formulary and medical policy considerations regarding coverage or reimbursement. This type of dossier is a comprehensive collection of…
Promotional review is traditionally accomplished by utilizing groups of professionals that meet a few times per week to review assets. It generally takes several weeks to approve an asset, and…